Last reviewed · How we verify

NCT07074041

Radiomic Analysis in OCT Imaging of Acquired Vitelliform Lesions.

Completed Last updated 4 September 2025
What this trial tests

trial in VITELLIFORM LESIONS in 50 participants. Completed in 31 January 2025.

Timeline
1 March 2022
Primary endpoint
31 January 2025
31 January 2025

Quick facts

Lead sponsorFederico II University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date1 March 2022
Primary completion31 January 2025
Estimated completion31 January 2025
Sites1 location across Italy

Conditions studied

Sponsor

Federico II University

Who can join

18 and older, any sex, with VITELLIFORM LESIONS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vitelliform lesions (VLs) are subretinal accumulations of yellowish material on fundoscopy that correspond to hyperautofluorescent material on fundus autofluorescence (FAF) and hyperreflective subretinal material on structural optical coherence tomography (OCT). VLs are characterised by dynamic changes with progressive resorption of material and are associated with the appearance of visual symptoms, such as reduced visual acuity. The appearance of symptoms and changes in the characteristics of the VLs on retinal imaging are the basis of a sophisticated differential diagnosis, especially to distinguish a neovascular from a non-vascular sub-type. To date, additional retinal imaging techniques can be helpful in performing differential diagnosis in unclear cases. Radiomics is a quantitative approach to medical imaging that can extract many features to improve medical diagnosis and assess response to treatment. The aim of this study is to evaluate the performance of radiomics in the diagnosis of dynamic changes in VLs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Federico II University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07074041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing